19532-69-5

Basic information

• Product Name: 2,2-Dithiobis(5-methoxybenzoic acid)
• CAS NO: 19532-69-5
• Molecular Formula: C₁₆H₁₄O₆S₂
• Molecular Weight: 366.416
• Mol File: 19532-69-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 560.8°Cat760mmHg
• Flash Point: 292.9°C
• Density: 1.5g/cm³
• CAS DataBase Reference: 2,2-Dithiobis(5-methoxybenzoic acid)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-Dithiobis(5-methoxybenzoic acid)(19532-69-5)
• EPA Substance Registry System: 2,2-Dithiobis(5-methoxybenzoic acid)(19532-69-5)

Safety Data

• Hazardous Substances Data: 19532-69-5(Hazardous Substances Data)

Usage

General Description

2,2-Dithiobis(5-methoxybenzoic acid) is a compound with the molecular formula C17H16O6S2. It is also known as DTMB and is a versatile chemical that is widely used in the pharmaceutical and electronics industries. DTMB is a dithio compound with antioxidant and radical scavenging properties, making it useful in protecting materials from degradation caused by free radicals and oxidation. It is also used as an intermediate in the synthesis of various organic compounds and as a reagent in organic chemistry reactions. In addition, DTMB has potential applications in the development of new drugs and in the field of material science for creating new functional materials.

Upstream product

• 6705-03-9 2-Amino-5-methoxybenzoic acid 

Downstream Products

• 177785-51-2 2,2'-dithiobis[5-methoxybenzoyl chloride] 
• 384339-80-4 C₇H₆O₃S 
• 100538-48-5 5,5'-dihydroxy-2,2'-disulfanediyl-di-benzoic acid 
• 793725-10-7 5-methoxydithiosalicylic acid di-2-chloroethyl amide 
• 80568-65-6 1-(2-Diethylamino-ethylamino)-7-hydroxy-4-methyl-thioxanthen-9-one; hydriodide 
• 80568-29-2 1-<<2-(dimethylamino)ethyl>amino>-7-hydroxy-4-methylthixanthenone 
• 80568-67-8 1-(2-Amino-ethylamino)-7-hydroxy-4-methyl-thioxanthen-9-one; hydriodide 
• 80568-56-5 ((2-(diethylamino)ethyl)amino)-7-methoxy-4-methyl-9H-thioxanthen-9-one 
• 80568-39-4 7-Hydroxy-1-[2-(2-hydroxy-ethylamino)-ethylamino]-4-methyl-thioxanthen-9-one 
• 80568-28-1 1-(2-Dimethylamino-ethylamino)-7-methoxy-4-methyl-thioxanthen-9-one 
• 80568-32-7 2-<(5-chloro-2-methylphenyl)thio>-5-methoxybenzoic acid 
• 86456-29-3 1-<<2-(diethylamino)ethyl>amino>-7-(toluenesulfonyloxy)-9H-thioxanthen-9-one 
• 86456-33-9 1-<<2-(diethylamino)ethyl>amino>-4-(hydroxymethyl)-7-(toluenesulfonyloxy)-9H-thioxanthen-9-one 
• 101339-44-0 1-<<2-(dimethylamino)ethyl>amino>-4-(hydroxymethyl)-7-(toluenesulfonyloxy)-9H-thioxanthen-9-one 

Relevant articles and documents

COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS

The present teachings provide compounds of Formulae I and II: and and pharmaceutically acceptable salts, hydrates, complexes, esters, and prodrugs thereof, wherein R1, R1', R2, R2', R3, R3', and X are as defined herein. The present teachings also provide methods of making the compounds of formulae I and II, and methods of treating RyR-associated conditions, disorders, and diseases that include administering a therapeutically effective amount of a compound of formula I or II to a subject in need thereof. In addition, the present teachings relate to methods of reducing the open probability of a ryanodine receptor, and methods of reducing Ca2+ release across a ryanodine receptor (e.g., into the cytoplasm of a cell), by contacting a compound of formula I or II with a ryanodine receptor.

Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.